XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Treasury Stock
Accumulated Deficit
Total UpHealth, Inc. Stockholders’ Equity
Noncontrolling Interests
Balance at beginning of period (in shares) at Dec. 31, 2022   15,054,000          
Balance at beginning of period at Dec. 31, 2022 $ 106,137 $ 2 $ 688,355 $ (17,000) $ (566,209) $ 105,148 $ 989
Balance at beginning of period (in shares) at Dec. 31, 2022       170,000      
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Equity award activity, net of shares withheld for taxes (in shares)   80,000          
Equity award activity, net of shares withheld for taxes (3)   (3)     (3)  
Issuance of common stock (in shares)   1,650,000          
Issuance of common stock in connection with 2023 private placement, net of issuance costs of $348000 4,155   4,155     4,155  
Stock-based compensation 989   989     989  
Net income (loss) (7,635)       (8,083) (8,083) 448
Distribution to noncontrolling interests (44)           (44)
Balance at end of period (in shares) at Mar. 31, 2023   16,784,000          
Balance at end of period at Mar. 31, 2023 $ 103,599 $ 2 693,496 $ (17,000) (574,292) $ 102,206 $ 1,393
Balance at end of period (in shares) at Mar. 31, 2023       170,000      
Balance at beginning of period (in shares) at Dec. 31, 2023 18,671,142 18,671,000          
Balance at beginning of period at Dec. 31, 2023 $ 55,104 $ 2 696,150 $ (17,000) (624,048)    
Balance at beginning of period (in shares) at Dec. 31, 2023       170,000      
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Equity award activity, net of shares withheld for taxes (in shares)   140,000          
Stock-based compensation 1,260   1,260 [1]        
Net income (loss) $ 25,421       25,421    
Balance at end of period (in shares) at Mar. 31, 2024 18,811,398 18,811,000          
Balance at end of period at Mar. 31, 2024 $ 81,785 $ 2 $ 697,410 $ (17,000) $ (598,627)    
Balance at end of period (in shares) at Mar. 31, 2024       170,000      
[1] Includes $0.3 million from the acceleration of equity awards, which is included in net income from discontinued operations, net of tax, in the unaudited condensed consolidated statements of operations.